Erythropoiesis is a commonly used model system to study cell differentiation. During erythropoiesis, pluripotent adult human hematopoietic stem cells (HSCs) differentiate into oligopotent progenitors, committed precursors and mature red blood cells 1 . This process is regulated for a large part at the level of gene expression, whereby specific transcription factors activate lineage-specific genes while concomitantly repressing genes that are specific to other cell types 2 . Studies on transcription factors regulating erythropoiesis are often performed using human and murine cell lines that represent, to some extent, erythroid cells at given stages of differentiation [3] [4] [5] . However transformed cell lines can only partially mimic erythroid cells and most importantly they do not allow one to comprehensibly study the dynamic changes that occur as cells progress through many stages towards their final erythroid fate. Therefore, a current challenge remains the development of a protocol to obtain relatively homogenous populations of primary HSCs and erythroid cells at various stages of differentiation in quantities that are sufficient to perform genomics and proteomics experiments.
Isolate CD34 + cells by positive immunomagnetic selection (Figure 1-Step 1)
We use the CD34 Microbead Kit (containing a solution of Microbeads conjugated to monoclonal mouse human CD34 antibodies and a solution of FcR Blocking Reagent containing human IgG) in combination with two LS Mini-Macs columns, the autoMACS Running Buffer and a MiniMACS Separator (Table 1) . Below we describe our protocol starting from 2.3x10 8 MNCs. If different numbers of cells are used, volumes should be scaled-up or down accordingly. In addition, for up to 2x10 8 MNCs a MS MiniMacs column can be used instead of the LS MiniMacs column. Keep cells and reagents cold (4-8°C) to prevent capping of antibodies on the cell surface and non-specific cell labeling.
Erythroid differentiation in cell culture
CD34 + cells are cultured in supplemented IMDM medium with sequential supply of hydrocortisone and specific combinations of cytokines according to a four-step protocol adapted from 6 ( Figure 1- Step 2). A series of tests is performed throughout the procedure to verify cell growth and erythroid differentiation.
The number of CD34 + cells required to start a culture is variable, depending on the scale of the experiment. Typically, for gene expression studies we perform a small-scale culture starting with 0.1x10 6 CD34 + cells in 10 ml medium and maintaining small volumes by freezing extra cells throughout the procedure. For studies where protein extraction is required, cultures are performed at a larger scale. Here we describe a large-scale experiment where we start with~7x10 6 CD34 + cells isolated from leukapheresis. Sterile conditions are used throughout. See Tables 1, 2 and 3 for reagents.
1. Prepare reagents 2.
Step 1: Day 0-11 Hematopoietic cells are grown in supplemented IMDM medium containing hydrocortisone (HC), stem cell factor (SCF), interleukin 3 (IL-3) and erythropoietin (EPO) ( Table 3) . MS-5 murine bone marrow stromal cells (Table 1) a. Prepare the supplemented IMDM medium as described in Table 2 and freeze aliquots of 40 ml at -20°C (can be done in advance). b. Prepare stock solutions of hydrocortisone and cytokines as described in Table 3. • Day 0:
a. Pre-warm 120 ml of supplemented IMDM medium and add HC, SCF, IL-3 and EPO (Table 3) . b. Thaw 7x10 6 CD34 + cells by first placing the vial(s) in a 37°C water bath. While the cells are still frozen, add 1 ml of pre-warmed medium and transfer the cells to a 15 ml conical tube. Wash the vial with 2 ml medium and transfer to the 15 ml tube. c. Add 6 ml medium to the cell suspension, mix by inverting the tube and spin at 200 g for 5 min. d. Aspirate the supernatant and resuspend the cell pellet in 10 ml fresh medium. e. Count living cells using a hemocytometer after mixing 10 μl of cell suspension with 10 μl Trypan Blue solution (Table 1) . NB: Cell death is about 25% during thawing, so the concentration of live cells should be~0.5x10 6 cell/ml. f. Save approximately 3 ml of cell suspension for tests (see paragraph 6). g. Transfer the remaining 7 ml into a T-175 flask and add 63 ml of medium to have 0.05x10 6 cell/ml in 70 ml and place the flask in an incubator at 37°C.
• Day 1: a. Pre-warm 85 ml of MS-5 cell culture medium: αMEM with Glutamax (Table 1) , 10% FBS and 100 U/ml of penicillin and 100 μg/ml of streptomycin. b. Prepare three 150mm x 25mm round culture dishes, each seeded with 2x10 6 MS-5 cell in 25 ml medium to obtain 0.08x10 6 cell/ml and place in a 37°C incubator. 6 cell/ml in supplemented IMDM medium containing 10% DMSO and stored in liquid nitrogen.
• Day 10: a. Count hematopoietic cells with Trypan blue to exclude dead cells, and harvest the necessary number of cells (i.e.~5 ml of culture) for tests (see paragraph 6). NB: Cell density should be~1x10 6 cell/ml.
• Day 11: a. Count erythroid cells with Trypan blue to exclude dead cells. NB: Cell density should be~1.5x10 6 cell/ml. b. Pre-warm 1L of 1xPBS, 400ml of supplemented IMDM medium and 5L of supplemented IMDM medium containing EPO (Tables  2 and 3 ) at 37°C. c. Reserve a volume of culture equivalent to 15x10 8 cells (e.g.~4 flasks of 250 ml each) and proceed to e. d. Remaining cells (e.g. 15x10 8 ) are harvested in conical tubes, centrifuged at 450 g for 10 min., resuspended in cold MS30 buffer (Table 5 ) containing 0.1mM DTT using a maximum of 10 8 cell/ml and stored at -80°C after snap-freeze in liquid nitrogen for future use (e.g. nuclear extract). • Day 12: a. Count erythroid cells with Trypan blue to exclude dead cells, and harvest the necessary number of cells (i.e.~4 ml of culture) for tests (see paragraph 6) . NB: Cell density should be~0.6x10 6 cell/ml.
• Day 14: a. Count erythroid cells with Trypan blue to exclude dead cells, and harvest the necessary number of cells (i.e.~3 ml of culture) for tests (see paragraph 6) . NB: Cell density should be~0.9x10 6 cell/ml.
Step 4: Day 18-26
Erythroid cells are concentrated 3-4 fold to obtain 5-7x10 6 cell/ml final and maintained on MS-5 layer to allow maturation. 10% FBS is added in supplemented IMDM medium to allow a better preservation of cultured red blood cells (cRBCs).
Tests and representative results
The following tests are performed at the indicated days to verify proper cell proliferation and erythroid differentiation. Representative results presented on the figures were obtained using CD34 + cells isolated from leukapheresis.
Comments on the results:
Page 4 of 13 8 ) are harvested and resuspended in cold MS30 buffer (Table 5) • Day 16: a. Count erythroid cells with Trypan blue to exclude dead cells, and harvest the necessary number of cells (i.e.~4 ml of culture) for tests (see paragraph 6). NB: Cell density should be~0.6x10 6 cell/ml.
• Day 18: a. Count erythroid cells with Trypan blue to exclude dead cells, and harvest the necessary number of cells (i.e.~2 ml of culture) for tests (see paragraph 6) . NB: Cell density should be~1.7x10 6 cell/ml. b. Pre-warm 300ml of 1xPBS and 1.5L of supplemented IMDM medium (Table 2) Colony forming assays shown on Figure 4 are used to detect early and late hematopoietic progenitors during the first days of differentiation (Day 0 to Day 8). In addition to erythroid progenitors (CFU-E and BFU-E), we note that granulocyte-macrophage progenitors (CFU-GM) are significantly represented within the early CD34+ cells at Day 0. As differentiation proceeds, CFU-GM decrease significantly, and at Day 6 they have been completely replaced by erythroid progenitors BFU-E and CFU-E. It is also important to note that from Day 4 to Day 6, the early erythroid progenitors BFU-E are progressively replaced by their more differentiated counterparts CFU-E. By Day 10, erythroid cells have essentially lost their colony-forming capacity.
Finally, erythropoiesis is monitored by the expression of cell surface markers as shown in Figure 5 . Note: 1) the progressive loss of the hematopoietic stem/progenitor marker CD34; 2) the progressive acquisition and loss of the progenitor marker CD36; 3) the progressive acquisition and loss of the erythroid progenitor and reticulocyte marker CD71; and 4) the increase of the erythroid precursor and erythrocyte marker GPA. Other markers of erythroid differentiation include hemoglobin synthesis starting at Day 8 (measured by benzidine staining- Figure 5 ) and cell enucleation starting at Day 20 as measured by the loss of the DNA stain LDS ( Figure 5 ). Finally, erythroid differentiation can be measured by RT-qPCR of molecular markers such as the transcription factor TAL1 ( Figure 6B ) or the β-globin genes (data not shown).
Typically, 1 ml of cord blood / leukapheresis / bone marrow provides 0.35x10 5 / 0.5x10 5 / 1.1x10 5 CD34 + cells, which can theoretically produce 1.7x10 9 / 0.4x10 9 / 0.7x10 9 red blood cells with respective proliferation rates of 50,000 / 8,000 / 6,000. To obtain 50x10 6 red blood cells at the end of the differentiation procedure, you will need approximately 50 ml of culture medium.
Part II. Lentiviral mediated knockdown during ex vivo erythroid differentiation
Lentivirus is a tool of choice for gene transfer in human primary cells (see for example Amsellem et al. 9 ). Lentiviruses are often used to knockdown genes of interest in primary cells via delivery of targeted shRNA (see for example Laurenti et al. 10 ). In this protocol we target the transcription factor TAL1 in primary human erythroid cells. An shRNA with a scrambled sequence that does not correspond to any known gene is used as a negative control. GFP expression is used for evaluating transduction efficiency.
Preparation of lentiviral vector particles
To obtain lentiviral particles, human embryonic kidney 293T cells are cotransfected with three plasmids: one encompassing a second-generation virus packaging system coding for HIV-1 genes except env, vpr, vif, vpu and nef (i.e. psPAX2); one coding for the envelope of the vesicular stomatitis G-pseudotyped virus (i.e. pMD2G); and one lentiviral vector coding for the gene of interest (i.e. pBLOCK-it6-DEST(shTal1) coding for TAL1 shRNA, pBLOCK-it6-DEST(shScr) coding for scrambled shRNA or pWPIP coding for GFP) ( Table 4) . Lentiviral particles are collected from the cell culture supernatant of transfected 293T cells.
To avoid unwanted infection of cells, we perform all lentiviral experiments (preparation of viruses and infection) under a dedicated hood separate from other cell cultures. In addition, lentivirus-generated waste is discarded separately. Second generation lentiviruses described in this protocol are replication-incompetent and should be treated as Biosafety Level 2 organisms. Some institutions might have specific safety procedures regarding lentiviruses and we recommend that you follow established institutional guidelines.
Here we describe a protocol that will provide enough lentiviral particles to infect 1 to 2 millions primary erythroid cells at any given stage of differentiation. Volumes should be adjusted accordingly for scaling up or down. See Tables 4 and 5 • 44.8 μg expression vector for your gene of interest (e.g. shRNA or GFP-see Table 4) • 13.35 μg pMD2.G envelope vector.
• 33.48 μg psPAX2 packaging vector.
• Add enough sterile H2O to bring the volume to 1.116 ml.
d. Add enough sterile H2O to bring the volume to 1.116 ml. e. Add 109.8 μl CaCl2 2.5M and vortex to mix. f. In a 50 ml conical tube, add 1.116 ml of 2xHBS buffer (Table 5) . g. Under constant vortex agitation, add the DNA mixture dropwise into the 2xHBS buffer. h. Allow the precipitate to form at RT for 20 min. (no more than 30 min.). i. Add the 2.3 ml solution dropwise to the dish containing the 293T cells, swirl gently and transfer the cells to a 37°C incubator for 12-14 hours. j. Early the next morning, aspirate the medium and replace with 20 ml of fresh 37°C prewarmed medium.
a. Forty-eight hours after transfection, harvest 20 ml medium containing the lentivirus and place in a 50 ml conical tube. b. Add 20 ml of 37°C prewarmed medium to the 293T cells and return to the incubator. c. Centrifuge the viral supernatant at 450 g for 10 min. to remove any cell debris and transfer into a new 50 ml tube. Alternatively the supernatant may be passed through a 0.45μm filter. Store the cleared supernatant at 4°C.
Infection
Nucleated erythroid cells can be efficiently infected at any stage of differentiation as long as a high 50-100 MOI (multiplicity of infection) is used. Here we describe a typical experiment where lentiviruses expressing a TAL1 or scramble shRNA are used to infect erythroid cells at days 8 and 9 of differentiation using a MOI of 50 TU/cell. RNA is extracted every 24 hours to verify the level of TAL1 KD by RT-qPCR. GFP expression is measured in parallel by FACS for evaluating infection efficiency (see representative results on Figure 6 ).
• Day 0: a. Prepare three 15 ml conical tubes containing 1x10 6 erythroid cells each (i.e. one tube for TAL1 knockdown, one tube for scrambled negative control, one tube for GFP expression control). f. Add 900 μl supplemented IMDM medium containing SCF and EPO (Tables 2 and 3 ) in each tube. g. Transfer each sample in a 6-well plate and place in the 37°C incubator for 24 h.
• Day 1: Harvest cells in separate 15 ml tubes, spin them at 200 g for 5 min., remove the supernatant and repeat the infection (steps b to g above).
• Day 2: Wash the cells and resuspend them at 0.2x10 6 cell/ml into supplemented IMDM containing SCF and EPO and proceed as in Part I. Figure 6A illustrates the protocol for lentivirus infection of primary erythroid cells followed by RNA extraction. In one experiment, we have infected erythroid cells with lentivirus producing an shRNA targeted against the transcription factor TAL1 or a scrambled control 11 . Figure 6B shows that we were successful in knocking down 75% of TAL1 transcripts in primary erythroid cells. Please also note the increase of TAL1 transcript level from Day 9 to Day 12 in the scrambled control underlying the importance of this transcription factor during erythroid differentiation. In another experiment, we have infected erythroid cells with lentivirus expressing the GFP protein. Figure 6C shows that three days after infection, most erythroid cells (87%) are expressing GFP as measured by fluorescence under microscope and FACS. This indicates a high efficiency of infection in primary erythroid cells. We have previously infected CD34+ cells at Day 0 with a similar efficiency of infection (data not shown). The most important parameter for efficient transduction of primary cells is to use a high MOI (i.e. concentrated lentiviruses). If a low MOI is used (i.e. non-concentrated virus), the efficiency of transduction will decrease. thrombospondin receptor, present on progenitor cells; CD71: transferrin receptor, present on erythroid progenitors and reticulocytes; GPA: glycophorin A, present on erythroid precursors and erythrocytes; Benzidine: hemoglobin stain; LDS: laser dye styryl, DNA stain. • Add Milli-Q water.
Representative results

Materials
• Adjust pH to exactly 7.11-7.13 by adding NaOH solution and add milli-Q water up to 100 ml.
• Refine the pH to 7.11-7.13.
• Filter sterilize, make 10 ml aliquots and store at -200C
• 280 mM
• 100 mM • 1.5 mM Table 5 .
Discussion
A number of methods have been used previously to differentiate erythroid cells in culture with variable degrees of success. For example, some protocols without co-culture on MS-5 allows expansion of erythroid cells but are not efficient in producing fully mature enucleated red blood cells [12] [13] [14] [15] [16] [17] . While other methods allow efficient enucleation, it is at the expense of proliferation 18, 19 . The method we have used here, initially developed by the Douay laboratory 6 , combines an initial liquid culture step, which prolongs cell amplification during early stages of erythroid differentiation and thus provides us with large numbers of early progenitors (necessary for genomics and proteomics studies), and a second step of co-culture on MS-5 mesenchymal cells, which is important to maximize hemoglobin synthesis and to obtain complete enucleation of red blood cells. Two limitations of our method are 1) the still insufficient degree of amplification at the earliest stages of differentiation, which so far has prevented us to fully characterize the very early erythroid progenitors at the protein level and 2) the high cost of performing this protocol, particularly on a large-scale.
The quality of cell culture reagents and cytokines is essential for ex vivo erythroid differentiation. Notably, the use of BIT (Table 2) as a serum replacement is critical. Indeed in our experience the use of BIT eliminated batch-to-batch variations that we experienced previously (likely due to differences in reagent purity) when using separate sources of Bovine serum albumin, Insulin and Transferrin. Another critical point is the quality of the MS-5 layer used for co-culture of erythroid cells. Indeed, MS-5 cells must be 70% confluent when erythroid cells are added and must be changed every 3-4 days. If MS-5 cells are too confluent, erythroid cells will not grow and differentiate properly. In addition, unhealthy MS-5 cells tend to detach, making the harvesting of erythroid cells difficult.
Previous methods have used retrovirus for gene-delivery in hematopoietic stem/progenitor cells in culture. However, retroviruses infect only dividing cells and are therefore not efficient in infecting the mainly quiescent CD34 + cells isolated from cord blood, bone marrow or leukapheresis 20 . The main advantage of lentiviral approaches for gene-delivery is that it allows an efficient infection of cells independently of their proliferation status 7, 21 . Our lentiviral-mediated gene delivery allows one to efficiently knockdown or over-express specific transcription factors that can modify cell fate. Appropriate phenotypic analyses (cellular and molecular) can be devised after infection to reveal particular phenotypes. In addition, growth conditions may be altered to favor particular cell-types after infection. Along these lines, in this protocol we have chosen not to use any method to select lentivirus-infected cells for two main reasons: 1) our infection efficiency is very high ( Figure 6C ) and 2) we are concerned that the methods used to select lentivirus-infected cells (e.g. cell-sorting or antibiotic) are biased towards surviving/proliferating cells that are able to express either the antibiotic-resistance gene or the fluorescent marker at high levels thereby concealing a potential apoptotic phenotype.
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